T. Rowe Price Investment Management Inc. Has $2.26 Billion Position in Cencora, Inc. $COR

T. Rowe Price Investment Management Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 160.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,700,091 shares of the company’s stock after buying an additional 4,123,795 shares during the quarter. Cencora accounts for about 1.4% of T. Rowe Price Investment Management Inc.’s investment portfolio, making the stock its 9th largest position. T. Rowe Price Investment Management Inc. owned approximately 3.44% of Cencora worth $2,262,956,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora during the fourth quarter worth $25,000. Oakworth Capital Inc. acquired a new position in shares of Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC acquired a new position in shares of Cencora in the 4th quarter valued at $27,000. Archer Investment Corp increased its stake in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC acquired a new stake in Cencora during the 4th quarter worth about $29,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.8%

NYSE:COR opened at $271.99 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The stock’s 50-day moving average is $285.65 and its two-hundred day moving average is $324.72. The stock has a market cap of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Citigroup reduced their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research report on Friday, May 8th. Robert W. Baird cut their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, Barclays decreased their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research note on Wednesday, June 10th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.